Last reviewed · How we verify
Elunate®
Elunate is a small molecule inhibitor of the serine protease inhibitor, serpin family F member 5 (SERPINFB).
Elunate is a small molecule inhibitor of the serine protease inhibitor, serpin family F member 5 (SERPINFB). Used for Advanced or metastatic non-small cell lung cancer, Advanced or metastatic gastric cancer.
At a glance
| Generic name | Elunate® |
|---|---|
| Also known as | Fruquintinib |
| Sponsor | Hutchmed |
| Drug class | serine protease inhibitor |
| Target | SERPINFB |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Elunate works by inhibiting the activity of SERPINFB, which is involved in the regulation of angiogenesis and tumor growth. This inhibition leads to the reduction of tumor growth and metastasis.
Approved indications
- Advanced or metastatic non-small cell lung cancer
- Advanced or metastatic gastric cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elunate® CI brief — competitive landscape report
- Elunate® updates RSS · CI watch RSS
- Hutchmed portfolio CI